Ollin Biosciences Announces $330M Series B to Accelerate OLN324 for DME and Wet AMD
AUSTIN, TX, June 24, 2026 Ollin Biosciences has announced the successful completion of an oversubscribed $330 million Series B...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
AUSTIN, TX, June 24, 2026 Ollin Biosciences has announced the successful completion of an oversubscribed $330 million Series B...
WARSAW, Poland, June 3, 2026 Ingenix, an emerging artificial intelligence company focused on transforming drug discovery through advanced biological...
LONDON, May 12, 2026 Isomorphic Labs has secured a massive $2.1 billion Series B funding round to accelerate the...
CAMBRIDGE, UK, April 8, 2026 Immutrin Ltd has successfully raised £65 million ($87 million) in an oversubscribed Series A...
ENCINITAS, California, United States, April 7, 2026 Kiora Pharmaceuticals, Inc. announced the successful completion of a private placement financing...
CAMBRIDGE, UK, March 31, 2026 Semarion, a University of Cambridge spin-out company, has announced the successful raise of $3.8...
CAMBRIDGE, UK, March 17, 2026 Mestag Therapeutics has announced a $40 million financing round to advance its first-in-class oncology...
Redwood City, CA – March 17, 2026 – R1 Therapeutics has officially emerged from stealth mode, announcing an oversubscribed...
HOUSTON, Texas, Dec. 10, 2025 — Moleculin Biotech, a clinical-stage company developing novel oncology drug candidates including Annamycin for...
San Francisco, CA – December 3, 2025 — Excelsior Sciences has raised $95 million in new funding to accelerate...
